Biosimilars LatAm – Brazil 2024

The 2024 edition in Brazil aims to delve into the hurdles of producing monoclonal antibodies locally, discuss effective strategies for navigating the complex landscape of biosimilar licensing in Brazil, and explore the economic implications of biosimilar usage, focusing on cost savings, accessibility, and the evolving market dynamics in the country.

 

Plan Your 1-to-1 Meetings with JackLeckerman App

1. JackLeckerman App: Login & Meeting Notifications

Download the JackLeckerman App and sign up.

Check your email for the login details, or use the “Forgot Password” option to retrieve them.

You will receive meeting reminders on your mobile over the 2 days.

These reminders will include meeting requests, meeting confirmations, and messages from other attendees and the coordinator.

2. Attendee list to Plan Your Meetings

Browse the attendee list and select someone for a 10-minute 1-to-1 Meeting request.

Meeting requests close one hour before each Networking session in the program.

3. Managing Meeting Requests, Your Meetings Schedule

Accept or decline meeting requests through the “Meetings” button.

Check your scheduled meetings for the upcoming networking break.

4. Meeting Point Location in the Coffee Break Area

Go to the coffee break area and find the table number to meet your colleague

Who will
you meet?

 

More than:

Participants

Companies

HCPs

Patients

Academy

Investors

Institutions

Associations

Service Providers

Government Agencies

Industry Executives from Latam

From these areas:

  • Biosimilars
  • Biobetters
  • Biotechnology
  • Biotherapeutics
  • Analytical science
  • Regulatory compliance
  • Quality Control
  • Clinical immunology
  • Scientific Affairs
  • Pharmacovigilance
  • Research
  • Regulatory
  • Business Development
  • Marketing

Program at a Glance

Biosimilar Regulatory Updates

Invited: ANVISA

The Benefits of Mexico's New Regulatory Certainty Strategy
Brazil's Industry Contributions to CEPAL
Challenges in Local Production of Monoclonal Antibodies
Navigating the Landscape of Biosimilar Licensing: Strategies for Successful Market Entry in Brazil
Economic Impacts of Biosimilar Administration in Brazil: Cost Savings, Access, and Market Dynamics
From Brazil to Europe: Strengthening a Transcontinental Bond

Invited: INFARMED & AEMPS & MHRA

Harmonization and Reliance Efforts in South America

Invited: Regulatory Agencies of Reference

Full Programme in the PDF Agenda

Download Agenda

Speaker Board in 2023

Sponsors

Merck

We are a vibrant science and technology company. Science is at the heart of everything we do, it drives the discoveries we make and the technologies we create. For more than 350 years, curiosity has been driving us to deliver excellence to patients and customers – and to imagine the future.

Terumo

As Part of Terumo Medical Care Solutions, the Pharmaceutical Solutions Division develops patient-oriented parenteral delivery solutions for therapeutic performance and safety.

Globally trusted for quality and precision, we offer pharmaceutical and medical device manufacturers around the world comprehensive product design and development services.

We have decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to product commercialization to optimize critical aspects of parenteral drug delivery.

Innovation and creativity are central to our value proposition. Our expert teams lead the industry in developing and manufacturing advanced, high-performing infusion and injection technologies, including CDMO services for all parenteral applications.  

We listen. We question. We deliver. 

UDIBI

With 60+ dedicated scientists and support personal, UDIBI is a third-party laboratory authorized by the Mexican Regulatory Agency (COFEPRIS) to conduct analytical services for the pharmaceutical and medical devices industries. We also provide consulting services on antibody engineering and development of antibody-based therapeutics. With the support from government and private investment we have developed a portfolio of biotherapeutics that includes a product in the market and several therapeutic antibodies in diverse phases of discovery, optimization and preclinical development. In response to COVID-19 pandemic, UDIBI developed and commercializes the only 100% Mexican diagnostic kit to detect anti-SARS-CoV-2 antibodies with approval by COFEPRIS for commercialization in Mexico.

Cytiva

Cytiva is a global provider of technologies and services that help advance and accelerate the development and production of therapeutic products. Promoting training, speed and efficiency for research and production workflows, allowing the delivery of innovative medicines to patients.

Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros according to preliminary figures. At the end of 2019, more than 9,000 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.

Photo Gallery from Previous Events

Testimonials

Previous Forums

Keep me updated